Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

7.05
+0.08001.15%
Volume:350.03K
Turnover:2.46M
Market Cap:909.45M
PE:-1.85
High:7.11
Open:7.04
Low:6.90
Close:6.97
52wk High:31.35
52wk Low:4.28
Shares:129.00M
Float Shares:97.15M
Volume Ratio:0.40
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:2.01
PE(LYR):-2.46

Loading ...

Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data

Reuters
·
5 hours ago

Alumis Says Phase 3 Data Show Envudeucitinib Delivers 54% PASI 100 Response at Week 48 in Psoriasis Trial

Reuters
·
7 hours ago

Alumis - over 80% of Onward3 Patients Maintain Clear or Almost Clear Scalp Skin at 48 Weeks

THOMSON REUTERS
·
7 hours ago

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

THOMSON REUTERS
·
7 hours ago

Alumis - Plans Nda Submission for Envudeucitinib in 4Q 2026

THOMSON REUTERS
·
7 hours ago

Alumis - Onward3 Shows 54% Pasi 100 Skin Clearance at Week 48 for Envudeucitinib

THOMSON REUTERS
·
7 hours ago

Alumis Initiated With Buy on TYK2 Opportunity; Envu’s Strong Psoriasis Profile Supports Unchanged $15 Price Target

TIPRANKS
·
Oct 05

Top Premarket Gainers

MT Newswires Live
·
Sep 10

Alumis Director Srinivas Akkaraju Reports Disposal of 96,131 Common Shares Worth $1.01 Million

Reuters
·
Sep 10

Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)

TIPRANKS
·
Sep 10

Alumis to Present at Wells Fargo Annual Healthcare Investor Conference

Reuters
·
Sep 04

Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)

TIPRANKS
·
Sep 03

Alumis Cut to Neutral from Buy by Guggenheim

Dow Jones
·
Sep 03

Guggenheim Downgrades Alumis to Neutral From Buy

MT Newswires Live
·
Sep 03

Alumis downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
Sep 03

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)

TIPRANKS
·
Sep 03

Top Midday Gainers

MT Newswires Live
·
Sep 03

Alumis rises 10.7%

TIPRANKS
·
Sep 03

Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says

MT Newswires Live
·
Sep 02

Alumis Price Target Cut to $15.00/Share from $25.00 by HC Wainwright & Co.

Dow Jones
·
Sep 02